Jazz Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell JAZZ and other ETFs, options, and stocks.

About JAZZ

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. 

CEO
Renée D. Galá
CEORenée D. Galá
Employees
2,890
Employees2,890
Headquarters
Dublin, Dublin
HeadquartersDublin, Dublin
Founded
2005
Founded2005
Employees
2,890
Employees2,890

JAZZ Key Statistics

Market cap
15.47B
Market cap15.47B
Price-Earnings ratio
16.41
Price-Earnings ratio16.41
Dividend yield
—
Dividend yield—
Average volume
833.18K
Average volume833.18K
High today
$238.83
High today$238.83
Low today
$234.63
Low today$234.63
Open price
$235.67
Open price$235.67
Volume
788.26K
Volume788.26K
52 Week high
$266.38
52 Week high$266.38
52 Week low
$125.79
52 Week low$125.79

Stock Snapshot

As of today, Jazz Pharmaceuticals(JAZZ) shares are valued at $238.20. The company's market cap stands at 15.47B, with a P/E ratio of 16.41.

During the trading session on 2026-09-29, Jazz Pharmaceuticals(JAZZ) shares reached a daily high of $238.83 and a low of $234.63. At a current price of $238.20, the stock is +1.5% higher than the low and still -0.3% under the high.

Trading volume for Jazz Pharmaceuticals(JAZZ) stock has reached 788.26K, versus its average volume of 833.18K.

The stock's 52-week range extends from a low of $125.79 to a high of $266.38.

The stock's 52-week range extends from a low of $125.79 to a high of $266.38.

JAZZ News

Investing.com 5d
Goldman Sachs initiates Jazz Pharmaceuticals stock with buy rating - Investing.com

...

Goldman Sachs initiates Jazz Pharmaceuticals stock with buy rating - Investing.com
TipRanks 5d
Jazz Pharmaceuticals resumed with a Buy at Goldman Sachs

Goldman Sachs resumed coverage of Jazz Pharmaceuticals (JAZZ) with a Buy rating and $337 price target Goldman resumed coverage of the biotechnology sector, sayi...

TipRanks 5d
Jazz Pharmaceuticals Refinances Term Loan, Extends Maturities

An announcement from Jazz Pharmaceuticals ( (JAZZ) ) is now available. On September 23, 2026, Jazz Financing Lux S.à r.l., a wholly owned subsidiary of Jazz Ph...

Analyst ratings

87%

of 23 ratings
Buy
87%
Hold
13%
Sell
0%

More JAZZ News

Simply Wall St 6d
Jazz Pharmaceuticals Gains Put Its Valuation Story Back In Focus

Jazz Pharmaceuticals (JAZZ) has drawn investor attention after recent trading left the share price at $240.57, with mixed short term moves but strong longer ter...

Jazz Pharmaceuticals Gains Put Its Valuation Story Back In Focus

People also own

Based on the portfolios of people who own JAZZ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.